Conference Presentations
Author: Gibson et al.
Evaluation of the LITE-Risk Prognostic Model in Consolidation Durvalumab and Osimertinib-Treated NSCLC
Author: Gibson et al.
Characteristics, Treatment Patterns and Outcomes of Real-World NSCLC Exon 20 Insertions in HER1 (EGFR) and HER2 (ERBB2)
Author: Dean et al.
Adverse Events and Outcomes in Patients with Oncogenic Driver Mutation-positive NSCLC Receiving Targeted Therapy Following Immunotherapy
Author: Halperin et al.
Long-term Survivors with EGFR Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors: A Combined Canadian Cohort
Author: Cook et al.
Association Between Immune-Related Adverse Events and Survival in a Contemporary Metastatic Non-Small Cell Lung Cancer Cohort
Read MoreAuthor: Zhan et al.
Previously Treated Advanced-Disease NSCLC KRAS G12C From a Canadian Multi-Institutional Real-World Evidence Database (CARMA)
Read More2022 World Conference on Lung Cancer, Vienna, Austria
Author: Gibson et al.
Prognostic Utility of the ALI (Advanced Lung Index) in Crizotinib-Treated ALK and ROS1 Fusion-Positive NSCLC
Author: Gibson et al.
Impact of East Asian Ancestry on Response to First-Line Osimertinib: A Real-World Canadian Cohort
Author: Gibson et al.
Early Treatment Failure of Consolidation Durvalumab for Unresectable Stage III NSCLC: A Real-World Canadian Cohort
Author: Dean et al.
Precision Treatment of Non-Small Cell Lung Cancer has a profound impact on outcomes in a Canadian province.
Author: Litt et al.
A Retrospective Comparison of Survival Outcomes in EGFR-mutated, NSCLC Patients on Osimertinib +/- Brain Metastases
Read MoreAuthor: Litt et al.
Brain Metastases in EGFR-mutant NSCLC: Outcome of Osimertinib +/- Radiation Therapy in a Real-World Canadian Cohort
Read MoreAuthor: Ford-Sahibzada et al.
Sex as a Potential Independent Prognostic Factor in Non-Small Cell Lung Cancer Survival
Read MoreAuthor: Elegbede et al.
Pattern of subsequent treatment and outcomes in relapsed PD-L1 high NSCLC pre-treated with pembrolizumab
Read More2022 American Society of Clinical Oncology, Boston, MA, USA
Author: Meyers et al.
Impact of performance status on survival outcomes and health care utilization in patients with advanced non–small cell lung cancer treated with immune checkpoint inhibitors.
Read More2022 European Lung Cancer Congress, Virtual
Author: Elegbede et al.
Pembrolizumab versus Best Supportive Care Survival Outcomes in ECOG Performance Status 2 NSCLC Patients
Read More